28521254|t|CS - PEG decorated PLGA nano-prototype for delivery of bioactive compounds: A novel approach for induction of apoptosis in HepG2 cell line
28521254|a|Polymer - based nanoparticles are used as vectors for cancer drug delivery. The bioactive compounds (quercetin, ellagic acid and gallic acid) are well known to be not only antioxidants but also chemopreventive candidates against various types of cancers. To circumvent the low bioavailability and the short half-life time obstacles, we hypothesized a novel PLGA nano-platform functionalized with CS and PEG to encapsulate these phytochemicals. This encapsulation will protect the compounds from the phagocytic uptake and deliver PLGA-CS-PEG nano-prototype with high biodegradability and biosafety. Three consequent types of PLGA-based nanocomposites were prepared and characterized. Furthermore, we investigated the newly synthesized nano-formulations against human hepatocellular carcinoma (HepG2) and colorectal cancer (HCT 116) cell lines using cell growth inhibition assays, followed by apoptosis and necrosis assays using flow cytometry to detect the underlying mechanism of HepG2 cell death. Through Malvern Zeta Sizer, we recorded that the average diameters of the nano-prototypes ranged from 150 to 300nm. The cytotoxic activity of quercetin, ellagic acid, and gallic acid - encapsulated PLGA, PLGA-CS, and PLGA-CS-PEG nano-prototypes it has been found that they reduce the IC50s of the HepG2 cells values by 2.2, 2.9, 2.8- folds, 1, 1.5, 2.7- folds, and 0.9, 0.7, 1.5- folds, respectively. Mechanistically, the nano-platforms of quercetin seem to be dependent on both apoptosis and necrosis, while those of ellagic acid and gallic acid are mainly dependent on apoptosis. CS - PEG -blended PLGA nano-delivery system of quercetin, ellagic acid and gallic acid can potentiate apoptosis-mediated cell death in HepG2 cell line.
28521254	0	2	CS	T109,T121	C0162969
28521254	5	8	PEG	T109,T121,T122	C0032483
28521254	19	38	PLGA nano-prototype	T109,T122	C0071599
28521254	43	51	delivery	T070	C3850077
28521254	55	74	bioactive compounds	T123	C0574031
28521254	78	83	novel	T080	C0205314
28521254	84	92	approach	T082	C0449445
28521254	97	106	induction	T169	C0205263
28521254	110	119	apoptosis	T043	C0162638
28521254	123	138	HepG2 cell line	T025	C2717940
28521254	139	146	Polymer	T104,T122	C0032521
28521254	149	154	based	T169	C1527178
28521254	155	168	nanoparticles	T073	C1450054
28521254	173	177	used	T169	C1524063
28521254	181	188	vectors	T082	C0442335
28521254	193	199	cancer	T191	C0007097
28521254	200	213	drug delivery	T169	C0039798
28521254	219	238	bioactive compounds	T123	C0574031
28521254	240	249	quercetin	T109,T121,T127	C0034392
28521254	251	263	ellagic acid	T109,T121,T123	C0013900
28521254	268	279	gallic acid	T109,T130	C0016979
28521254	311	323	antioxidants	T121	C0003402
28521254	333	359	chemopreventive candidates	T121	C1516463
28521254	360	367	against	T080	C0521124
28521254	368	375	various	T081	C0439064
28521254	376	381	types	T080	C0332307
28521254	385	392	cancers	T191	C0007097
28521254	412	415	low	T080	C0205251
28521254	416	431	bioavailability	T081	C0005508
28521254	440	445	short	T081	C1806781
28521254	446	455	half-life	T079	C0018517
28521254	456	460	time	T079	C0040223
28521254	461	470	obstacles	T169	C0332206
28521254	490	495	novel	T080	C0205314
28521254	496	514	PLGA nano-platform	T109,T122	C0071599
28521254	515	529	functionalized	T169	C0205245
28521254	535	537	CS	T109,T121	C0162969
28521254	542	545	PEG	T109,T121,T122	C0032483
28521254	549	560	encapsulate	T080	C0205223
28521254	567	581	phytochemicals	T109,T123	C0577749
28521254	588	601	encapsulation	T067	C2348438
28521254	607	614	protect	T033	C1545588
28521254	619	628	compounds	T121	C1254351
28521254	638	655	phagocytic uptake	T043	C3888108
28521254	660	667	deliver	T070	C3850077
28521254	668	694	PLGA-CS-PEG nano-prototype	T121	C1254351
28521254	705	721	biodegradability	T080	C0205556
28521254	726	735	biosafety	T080	C0205556
28521254	754	759	types	T080	C0332307
28521254	763	788	PLGA-based nanocomposites	T121	C1254351
28521254	794	802	prepared	T052	C1521827
28521254	807	820	characterized	T052	C1880022
28521254	838	850	investigated	T169	C1292732
28521254	861	872	synthesized	T052	C1883254
28521254	873	890	nano-formulations	T073	C1707824
28521254	891	898	against	T080	C0521124
28521254	899	904	human	T016	C0086418
28521254	905	929	hepatocellular carcinoma	T191	C2239176
28521254	931	936	HepG2	T025	C2717940
28521254	942	959	colorectal cancer	T191	C1527249
28521254	961	968	HCT 116	T025	C1258005
28521254	970	980	cell lines	T025	C0682523
28521254	981	986	using	T169	C1524063
28521254	987	1009	cell growth inhibition	T043	C1512773
28521254	1010	1016	assays	T059	C1510438
28521254	1018	1029	followed by	T079	C0332283
28521254	1030	1039	apoptosis	T043	C0162638
28521254	1044	1052	necrosis	T042	C0027540
28521254	1053	1059	assays	T059	C1510438
28521254	1060	1065	using	T169	C1524063
28521254	1066	1080	flow cytometry	T059	C0016263
28521254	1084	1090	detect	T059	C0022885
28521254	1106	1115	mechanism	T169	C0441712
28521254	1119	1124	HepG2	T025	C2717940
28521254	1125	1135	cell death	T043	C0007587
28521254	1186	1193	average	T081	C1510992
28521254	1194	1203	diameters	T081	C1301886
28521254	1211	1226	nano-prototypes	T073	C1450054
28521254	1257	1275	cytotoxic activity	T059	C1551412
28521254	1279	1288	quercetin	T109,T121,T127	C0034392
28521254	1290	1302	ellagic acid	T109,T121,T123	C0013900
28521254	1308	1319	gallic acid	T109,T130	C0016979
28521254	1322	1334	encapsulated	T080	C0205223
28521254	1335	1339	PLGA	T109,T122	C0071599
28521254	1341	1348	PLGA-CS	T121	C1254351
28521254	1354	1381	PLGA-CS-PEG nano-prototypes	T121	C1254351
28521254	1394	1399	found	T033	C0150312
28521254	1410	1416	reduce	T080	C0392756
28521254	1421	1426	IC50s	T081	C0600495
28521254	1434	1445	HepG2 cells	T025	C2717940
28521254	1446	1452	values	T081	C1522609
28521254	1471	1476	folds	T081	C1880833
28521254	1491	1496	folds	T081	C1880833
28521254	1517	1522	folds	T081	C1880833
28521254	1577	1586	quercetin	T109,T121,T127	C0034392
28521254	1598	1607	dependent	T080	C0851827
28521254	1616	1625	apoptosis	T043	C0162638
28521254	1630	1638	necrosis	T042	C0027540
28521254	1655	1667	ellagic acid	T109,T121,T123	C0013900
28521254	1672	1683	gallic acid	T109,T130	C0016979
28521254	1695	1704	dependent	T080	C0851827
28521254	1708	1717	apoptosis	T043	C0162638
28521254	1719	1721	CS	T109,T121	C0162969
28521254	1724	1727	PEG	T109,T121,T122	C0032483
28521254	1737	1741	PLGA	T109,T122	C0071599
28521254	1742	1762	nano-delivery system	T169	C0449914
28521254	1766	1775	quercetin	T109,T121,T127	C0034392
28521254	1777	1789	ellagic acid	T109,T121,T123	C0013900
28521254	1794	1805	gallic acid	T109,T130	C0016979
28521254	1810	1820	potentiate	T052	C2349975
28521254	1821	1839	apoptosis-mediated	T043	C0162638
28521254	1840	1850	cell death	T043	C0007587
28521254	1854	1869	HepG2 cell line	T025	C2717940